Drugs / ST316
last change May 2026 re-read 2 minutes ago

ST316

Developed for
colorectal cancer
Investigated by
Sapience Therapeutics

Trials 1 · a red edge is where a trial was stopped

202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05848739 Jun 2023 → May 2026 overdue colorectal cancer Sapience Therapeutics Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ST316 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05848739
Route Intravenous “ST316 administered IV” NCT05848739